share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  04/16 16:12
Moomoo AI 已提取核心信息
On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.
On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.
2024年4月16日,Clene Inc.宣布在VISIONARY-MS多发性硬化症(MS)长期延期试验中公布其CNM-Au8治疗的临床试验结果。研究结果已在2024年美国神经病学会年会上公布,表明CNM-Au8可能有助于多发性硬化症患者的修复和髓鞘再生。该公司通过其网站上的演示和海报分享了这些信息,还发布了新闻稿。这些材料是作为该公司向美国证券交易委员会提交的8-K表最新报告的证物提供的。Clene Inc. 强调,所提供的信息,包括证物,不应被视为出于监管目的提交的,也不得以引用方式纳入其向美国证券交易委员会提交的任何文件中。
2024年4月16日,Clene Inc.宣布在VISIONARY-MS多发性硬化症(MS)长期延期试验中公布其CNM-Au8治疗的临床试验结果。研究结果已在2024年美国神经病学会年会上公布,表明CNM-Au8可能有助于多发性硬化症患者的修复和髓鞘再生。该公司通过其网站上的演示和海报分享了这些信息,还发布了新闻稿。这些材料是作为该公司向美国证券交易委员会提交的8-K表最新报告的证物提供的。Clene Inc. 强调,所提供的信息,包括证物,不应被视为出于监管目的提交的,也不得以引用方式纳入其向美国证券交易委员会提交的任何文件中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息